OT4B

OT4B is a private, patient-founded biotech company based in Paris, France, dedicated to developing oxytocin for Prader-Willi syndrome, a rare genetic disorder. The company is advancing a clinical development program in partnership with Toulouse University Hospital, built upon over a decade of academic research. Its strategy targets the severe neonatal phase of PWS first, aiming to improve feeding, behavior, and social interaction disorders, with the goal of making a treatment accessible to patients as soon as possible. OT4B represents a unique model of patient community-driven drug development for a high-unmet-need rare disease.

Clinical development program based on the therapeutic application of oxytocin for Prader-Willi syndrome, built upon a hypothesis of oxytocinergic system dysfunction and aimed at early intervention as a potential disease modifier.

The competitive landscape for a Prader-Willi syndrome treatment is currently sparse, with no approved drugs targeting the core symptoms. Competition exists from academic research groups and a few small biotefs exploring other mechanisms (e.g., cannabinoids, GLP-1 analogs for hyperphagia). OT4B's lead in clinical development with oxytocin, backed by over a decade of academic research, provides a first-mover advantage in a nascent field.